ADMA Biologics rises after rejecting short-seller's claims

Shares of biotech firm ADMA Biologics ADMA.O rise 12.44% to $9.32 premarket

Co issues statement against a March 24 report by short seller Culper Research, rejecting what it called false and misleading claims about its business

Says demand for Asceniv, its antibody treatment for immune-deficient patients, has been rising for more than two years and is now at a record high

Says the amount of product held by distributors is normal for the industry and reflects the need to keep enough supply on hand because the drug takes a long time to make

Adds it received clean audit opinions for 2024 and 2025 and there have never been any undisclosed related party transactions in violation of U.S. securities laws

ADMA shares were up over 6% in 2025